HIV-1 infection sets up a complex dynamic equilibrium between viral replication and the HIV-1-specific immune response. In the absence of antiretroviral therapy, the high rate of viral replication, the associated depletion of CD4 + T cells, and the high mutation rate of the virus combine to eventually overwhelm the immune system. In certain cases, however, it appears that the immune system has the upper hand, and viral replication occurs at only very low levels. Two groups of individuals fall into this category: some long-term nonprogressors (LTNPs) who have either very low or undetectable levels of plasma virus (1) (2) (3) , and patients who are treated with highly active antiretroviral therapy (HAART) shortly after seroconversion who subsequently discontinue therapy (4, 5) .
Much recent effort has been directed toward studying the HIV-specific immune response of these subjects in the hope of finding clues that will be helpful in designing vaccines. Viral antigen-specific CD4 + and CD8 + T cells play an important role in HIV-specific immunity. The receptors on these cells recognize processed viral peptides that are presented by MHC molecules on the surfaces of antigen presenting cells. While considerable progress has been made regarding the mechanism by which responding T cells control viral replication, less is known about the role of the MHC genotype in patients who spontaneously control viremia.
Class I MHC polymorphisms and disease progression
MHC molecules are extremely polymorphic proteins that determine which processed peptides are presented to T cells. Recent studies have shown a link between MHC expression and the rate of progression of HIV-1 infection. HLA B*57 is one of three MHC class I alleles found to be independently associated with slow progression of HIV-1 disease in a study of two large cohorts (6) . Another recent study confirmed the high frequency of HLA B*57, and particularly the HLA B*5701 allele, in a subset of LTNPs with undetectable viral loads (3) . Eleven out of 13 such individuals were HLA B*5701 + whereas only 19 of 200 patients with progressive disease expressed this allele.
This association with class I molecules suggested that CD8 + cytotoxic T lymphocytes (CTLs) might play a role in slowing disease progression. Work by Goulder and colleagues demonstrated that the HIV-1-specific CTL response in these LTNPs was largely limited to HLA B*57-restricted viral epitopes (7). Migueles and colleagues confirmed this finding (3). Interestingly, these authors also showed that, whereas HLA B*5701 + individuals with progressive disease had as many HIV-1-specific CD8 + T cells as did LTNPs, CTL responses in progressors were often mediated by other class I MHC molecules; in LTNP subjects, these responses were more often associated with HLA B*5701-restricted epitopes (3). This suggests that the ability to focus the CTL response to HLA B*5701-associated epitopes promotes spontaneous control of viremia, perhaps because of differences in antigen processing and/or the T-cell receptor repertoire in LTNPs.
The apparent advantage of a narrowly restricted T-cell response is counterintuitive, especially in light of recent data from Carrington et al. (8) showing a correlation between heterozygosity at the three class I loci and delayed onset of AIDS following seroconversion. Multiple MHC alleles, which would increase the diversity of the peptides that were presented to T cells and result in a broad immune response, thus appear to be beneficial. In contrast, the work of Migueles and colleagues (3) suggests that a preventative vaccine consisting of peptides containing the identified haplotype-restricted epitopes would theoretically be superior to one containing conventional whole protein antigens in HLA B*57 + individuals.
T-helper responses and MHC class II polymorphisms
HIV-1-specific proliferative CD4 responses, which are largely absent in patients with chronic progressive disease, are seen in LTNPs (1, 2), suggesting that MHC class II molecules play at least an indirect role in the immune system's ability to control viremia. However, until recently, this role remained largely undefined. Chen MHC class II genotype and the control of viremia in HIV-1-infected individuals on highly active antiretroviral therapy children with slow progression but absent in all 14 children with rapid progression (9) . In addition, in a recent study of three adult cohorts, the HLA DRB1*1300-DQB1*0603 haplotype was the only class II genotype associated with slow progression (10) . In this issue of the JCI, Malhotra and colleagues help clarify the role of this allele in HIV-1-specific immunity (11). The authors followed a cohort of 21 acute seroconverters who were treated with HAART shortly after presentation. Such early treatment has been shown to preserve HIV-1-specific CD4 proliferative responses. Interestingly, all seven patients with the HLA DRB1*13-DQB1*06 haplotype maintained suppression of viremia to below the limit of detection of current ultrasensitive assays (50 copies of HIV-1 RNA/ml) on HAART over an 18-month period, compared with only 3 of 14 patients lacking this haplotype. As in prior studies (2, 5, 12) , all 21 patients were shown to have specific CD4 proliferative responses to the HIV-1 gag protein p24, but the responses were significantly stronger in the seven HLA DRB1*13-DQB1*06 + individuals. The results strongly suggest that the immune system continues to play a role in containing viremia in patients on HAART. This is a novel and surprising finding, as prior studies had shown a decline in the activity of HIV-1-specific CD8 + T cells (13) (14) (15) and had suggested a decline in the frequency of gag-specific CD4 + T cells in chronically infected patients on HAART (16) . The data suggest that boosting the immune response through therapeutic vaccination may help maintain the efficacy of HAART.
Identifying the relevant class II-restricted epitopes
Having thus demonstrated the influence of the DRB1*13-DQB1*06 haplotype on therapeutic outcome, Malhotra and colleagues (11) went on to map two DRB1*13-restricted epitopes, using p24-specific T-cell clones. The peptide gag 26 (amino acids 251-270), which contained two distinct epitopes, was found to bind with reasonably high affinity to 10 of 12 DRB1 molecules tested. The best binding, however, was to DRB1*13. Another epitope was found in the peptide gag 30 (amino acids 291-310), which is located in a very highly conserved region of the protein. ELISPOT analysis demonstrated that more than 50% of cells from p24-specific CD4 lines, generated from four DRB1*13 + acute seroconverters, responded to one or both of these peptides, suggesting that they contain immunodominant epitopes.
Finally, the authors showed that this haplotype was present in 9 of 18 LTNPs and that LTNPs with this haplotype have significantly stronger p24-specific CD4 + proliferative responses than those lacking it (11) . The authors suggest that strong immune responses to the immunodominant DRB1*13-restricted epitopes found in the p24 protein lead to control of viremia. The high affinity of gag 26 for HLA DRB1*13 results in better antigen presentation and hence a better immune response in patients expressing this allele. Therapeutic vaccination with peptide analogs of gag 26, engineered to bind with higher affinity to other HLA DR molecules, might therefore improve the immune response and block disease progression in individuals expressing other haplotypes.
It should, however, be noted that the current study examined only p24 responses. LTNPs have been shown to have proliferative responses to other HIV-1 antigens including p17, gp120, and gp66 (1, 17) . It is possible that HLA DRB1*13-restricted immunodominant epitopes present in these other molecules are equally as important in containing viremia as the two found in the p24 protein. If so, then vaccination with multiple peptides and/or peptide analogs may be needed. The epitopes found in p24 contained what appears to be an HLA DRB1*13-specific binding motif, with either tyrosine or isoleucine at position 1 and either arginine or glycine at position 4.
Prospects for fine-tuning HAART
The study of Malhotra et al. (11) has important clinical implications and should also lead to a better understanding of HIV-1 pathogenesis. In addition to the vaccination strategies outlined above, the data may be useful in stratifying patients who are to be treated with HAART. Since patients lacking the HLA DRB1*13 allele appear to be less likely to maintain complete viral suppression on a standard regimen, it may be beneficial to treat such patients with more potent cocktails of antiretrovirals. Given the toxicity of these drugs, such a strategy may be helpful in optimizing the risk-to-benefit ratio in individual patients.
Peptides containing immunodominant epitopes can be used to construct tetramers with HLA DRB1*13 molecules. These reagents could then be used as probes to monitor p24-specific CD4 + T cells in patients with this haplotype. Physical deletion of these cells can be distinguished from functional anergy in chronically infected patients with progressive disease. In addition, the emergence of viral escape mutants has been demonstrated in infected patients who had previously controlled viremia with strong CTL responses (18) (19) (20) . It would thus be instructive to look for mutations in the p24 immunodominant epitopes in HLA DRB1*13 + LTNPs who eventually develop progressive disease. Most importantly, the exciting idea that ongoing HIV-1-specific T-cell responses help to control viral replication, even in patients on HAART who have apparently undetectable levels of plasma virus, needs further study to determine whether immunologic interventions could prolong responses to this therapy.
